| | 645-05-6 Basic information More.. |
| Product Name: | Altretamine | | Synonyms: | RB-1515;WR-95704;2,4,6-Tris(dimethylamino)-1,3,5-triazine 96%;1,3,5-Triazine-2,4,6-triamine, N,N,N',N',N'',N''-hexamethyl-;1,3,5-tris(dimethylamino)-s-triazine;2,4,6-tris(dimethylamino)-s-triazin;2,4,6-Tris(Dimethylamino)-s-triazine;5-triazine-2,4,6-triamine,n,n,n’,n’,n’’,n’’-hexamethyl-3 | | CAS: | 645-05-6 | | MF: | C9H18N6 | | MW: | 210.28 | | EINECS: | 211-428-4 | | Mol File: | 645-05-6.mol |  |
Use
Altretamine is available in 50-mg capsules for oraladministration as a second-line treatment for ovarian cancer.The mechanism of action has not been firmly established, althoughthe spectrum of activity is similar to that for otheralkylating agents; however, cross-resistance is not seen.Cytotoxicity has been correlated with metabolism to give thecarbinolamines, which may form imines capable of crosslinking,or decompose to give formaldehyde, which may reactwith nucleophiles on DNA or proteins. The agent is well absorbedupon oral administration, well distributed, and highly(90%) plasma protein bound. The agent is extensively metabolizedin the liver by CYP to give demethylated metabolites via the previously mentioned carbinolamines. Elimination occursprimarily in the urine as mostly demethylated metaboliteswith a terminal elimination half-life of 4 to 10 hours.Myleosuppression and nausea/vomiting are dose-limitingtoxicities. Other adverse effects include lethargy, agitation,hallucinations, skin rash, and elevations in transaminase levels,flulike symptoms, abdominal cramps, and diarrhea.
- Altretamine
-
- $30.00
- 2026-05-29
- CAS:645-05-6
- Purity: 99.84%
- Supply Ability: 10g
- Altretamine
-
- $30.00
- 2026-05-29
- CAS:645-05-6
- Purity: 99.84%
- Supply Ability: 10g
- Altretamine
-
- $2.00
- 2026-04-10
- CAS:645-05-6
- Min. Order: 1KG
- Purity: 99% hplc
- Supply Ability: 500TONS
|
|
645-05-6
Recommend Suppliers |
|